To be precise, the research questions are whether mutations in MT-CYB and MT-ATP6 are more prevalent or pathogenic in Bangladeshi COVID-19 patients than in healthy individuals, and whether these mutations are associated with disease severity or clinical outcomes. The gene discussed is MCAT; the disease is COVID-19.